Search

everythinglearnresearchcommunity

for

Search:↓

The conversation discusses hair regrowth treatments, including stem cell exosomes, PRP, and PP405. Users question the effectiveness of the treatments and mention finasteride and minoxidil.

A double-blind clinical study that found ingestion of tocotrienols resulted in a 34.5% increase in hair regrowth compared to the placebo group, and discussion about potential side effects and cost of supplementation with vitamin E pills. The conversation noted that it may be more effective than commonly used treatments like minoxidil and finasteride.

Triple Hair Inc. developed a new topical treatment, TH07, combining Finasteride, Latanoprost, and Minoxidil for androgenic alopecia. Users discussed its effectiveness compared to other treatments and shared their own product combinations.

The post discusses the user's experience with hair loss treatment using finasteride, clobetasol propionate, and ketoconazole shampoo. The conversation warns about the potential side effects of clobetasol, a powerful topical steroid, and emphasizes its short-term usage.

AnagenInc is ready to produce a hair loss treatment called GT20029 if there is enough demand. People are discussing combining it with other treatments like finasteride and minoxidil, and some are concerned about the legitimacy and safety of gray market products.

The conversation discusses hair loss treatments, specifically Regenera stem cells and exosomes from 'Cellgenic' umbilical cord donors. The user has been using topical minoxidil 5% and 0.001% estradiol for a year without seeing effects, and another user mentions the importance of microneedling.

The user started using minoxidil foam daily after two years on finasteride and is managing seborrheic dermatitis with antifungal shampoo. They seek advice on moisturizing products that won't worsen their condition, with suggestions including gentle shampoos and light ceramide serums.

Oral biotin combined with topical minoxidil may increase hair growth rate, though the study was limited to healthy subjects and did not measure hair density. Some users report personal benefits from biotin, such as faster nail growth and healthier hair, but concerns about acne and study quality were also mentioned.

A user is seeking advice on a new topical hair loss treatment containing Minoxidil 3%, Finasteride 0.3%, Progesterone 1%, Hydrocortisone butyrate 0.1%, and Ketoconazole 0.5%. They are concerned about the systemic absorption of Finasteride and plan to do blood tests and a spermiogram before starting.

The conversation is about making topical finasteride using ethanol. The user is advised to use non-denatured or food-grade ethanol, as denatured ethanol may be harmful with prolonged skin exposure.

The user is seeking Malassezia-safe treatments for hair loss and currently uses a baby shampoo, a scalp tonic with antifungal ingredients, and aloe gel. They consider using Kirkland Minoxidil 5% drops and possibly consulting a doctor about Finasteride.

DHT causes hair loss by driving cells into senescence, and a polyphenol in black chokeberry may reverse this. A product using this theory is being considered for use alongside finasteride, minoxidil, and microneedling.

Users discuss making topical finasteride solutions by dissolving crushed tablets in ethanol and propylene glycol, with concerns about residue affecting effectiveness. They also mention using minoxidil and oral finasteride, noting some hair regrowth and no side effects from topical use.

New hair loss treatments include Breezula, PP405, ET-02, KX-826, GT20029, VDPHL01, and CosmeRNA, with some showing promise in reactivating stem cells and reversing greying. Breezula and VDPHL01 are highlighted as potential add-ons or alternatives to current treatments like finasteride and minoxidil.

Clascoterone in Winlevi, a topical AR antagonist, is being re-examined due to concerns about HPA axis suppression in adolescents, but it's unlikely to be banned for adult use in androgenetic alopecia (AGA). The European Medicines Agency recommended refusing Winlevi for acne vulgaris, but this may not affect Breezula's approval for AGA.

A new brand is seeking 10 U.S.-based individuals aged 25+ experiencing hair loss to test a topical product containing GHK-Cu and Acetyl Tetrapeptide-3. Participants must not be using other treatments like finasteride or minoxidil and will provide feedback and photos.

A potential treatment for hair loss that involves injecting fat into the scalp; the role of testosterone and estrogen in thinning fat tissue under the skin; research on using lard to treat androgenic alopecia, as well as PRP + ACELL/amniotic stem cell treatments; and ongoing clinical trials by doctors involved in the study.

The conversation discusses the use of peptides C60 and GHK-Cu for hair growth. Participants are sharing their experiences or knowledge about these treatments.

Finding acceptance of hair loss through psychedelics, and the potential benefits of shrooms. Discussions include sharing experiences with minoxidil, finasteride, nutrafol, laser therapy, micro needling, as well as mental health concerns such as depression, suicidal thoughts, and self-esteem.

The conversation is about using PTD-DBM and valproic acid for hair loss. The user is inquiring about the dosage of these treatments, noting that valproic acid is used at a 7.5% solution.

Lactic acid is not effective for hair growth when applied topically. JXL069, finasteride, and minoxidil are suggested as alternative treatments.

Kintor plans to release pyrilutamide foam and a plant-based Koshine by year-end, with GT20029 progressing in their pipeline. Users are pleased about the absence of propylene glycol (PG) in the new products.

The conversation is about the effectiveness of a hair loss treatment product containing 0.01% Latanoprost, with the user considering trying it as a vehicle for RU58841. The user questions whether the dosage is too low to be effective.

Hair loss discussion includes treatments like hinoki tree oil and procyanidin b2. Experiences and effectiveness of these treatments are shared.

PP405 is a promising molecule that may reactivate dormant hair follicles, potentially offering a new treatment for hair loss. It is in phase 2 trials, with possible availability between 2027 and 2030.

Finding a topical solution for hair loss, with specific treatments mentioned such as Minoxidil, Finasteride and RU58841.

PP405 is a potential hair loss treatment showing promising early results, with hopes for market release by 2028, but skepticism remains due to inconclusive data and past disappointments with similar products. Current treatments like Minoxidil and Finasteride have side effects, leading some to anticipate PP405 as a safer alternative, though its effectiveness compared to placebo is debated.

The conversation is about sourcing gray market compounds, gt20029 and pp405, for hair loss treatment. The user is interested in these compounds despite their unproven status and potential risks.

The user is using Minoxidil, RU58841, CB-03-01, WAY-316606, Ketoconazole, MK-677, and derma stamping to treat hair loss and has noticed new hair growth, especially around the temples and hairline. They apply different treatments at various times of the day and have seen improvements in skin condition and body hair texture.

A user is considering adding PRP and mesotherapy to their hair loss treatment and is deciding between two options: Promoitalia, which contains Phosphatidic acid, Riboflavin, and Superoxide dismutase, and the more expensive Melsmon, a human placenta derivative. They seek advice on which option to choose based on effectiveness and scientific backing.